Medtronic Launches New Neuro Oncology Surgical Imaging System Internationally
This week at the annual Congress of Neurological Surgeons (CNS),
Medtronic (NYSE: MDT) announced the Conformite Europeen (CE) mark and
international launch of the PoleStar® N30 Surgical MRI system, the
latest in neuro oncology surgical solutions. The PoleStar N30 System has
been submitted to the U.S. Food and Drug Administration for approval.
Providing real-time imaging in the operating room (OR), the PoleStar
Surgical MRI provides surgeons with targeting and navigational accuracy
despite the anatomy movement that may occur during a procedure. With
intra-operative imaging information, neurosurgeons have more confidence
to achieve maximum tumor resection, while avoiding critical areas of the
brain. Use of the PoleStar system may also reduce the need for revision
surgeries and the length of stay at the hospital for the patient.
“This is the next generation of intra-operative MRI providing
flexibility, enhanced ergonomics and confidence in the achievement of
surgical goals,” said Jim Cloar, vice president and general manager of
the Navigation division, part of the Surgical Technologies business at
Medtronic. “With its unique compact design, the PoleStar Surgical MRI
system allows neurosurgeons to benefit from intra-operative MR imaging
without the compromises inherent in other systems, such as extensive
renovation of the operating room or restrictions upon the surgeons'
choice of instruments.”
Dr. Moshe Hadani, Chairman of Neurosurgery, Sheba Medical Center in
Israel was a frequent user of the previous model of the PoleStar
Surgical MRI. “Recently we installed the PoleStar N30 System. We have
found the new PoleStar to have great improvements in ergonomics. The
scanner is smaller, easier to handle and it fits better into the OR
environment. Using the PoleStar, I have great confidence in the extent
of tumor resection prior to closing.”
More than 50 PoleStar systems have been installed in ORs worldwide since
2001. The launch of the PoleStar N30 is the culmination of six years of
research and development by Medtronic scientists and engineers working
with surgeon customers from leading hospitals and clinics.
ABOUT MEDTRONIC
Medtronic, Inc. (www.medtronic.com),
headquartered in Minneapolis, is the global leader in medical technology
– alleviating pain, restoring health and extending life for millions of
people around the world.
Any forward-looking statements are subject to risks and uncertainties
such as those described in Medtronic’s Annual Report on Form 10-K for
the year ended April 24, 2009. Actual results may differ materially from
anticipated results.
(c) 2009 Business Wire, Inc., All rights reserved. All of the news releases and other content contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. Any copying or reproduction (other than for an individual user's personal reference), redistribution, reposting or other transmission or communication is expressly prohibited without prior written permission of Business Wire, Inc
